Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population
Key facts
- Who runs it
- University of Oulu
- Where
- Finland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 68 people enrolled
- Started
- 1 Feb 2017
- Ended
- 18 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexmedetomidine
- Sedatives/Hypnotics,Other
- Record updated
- 20 December 2023
Who can take part
- Age
- 1 year to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patient age between ages 1year to 18 years
- A joint inflammation in 1-5 joints needing intra-articular corticosteroid injection diagnosed by pediatric rheumatologist
Who cannot take part
- Patients under the age of 1year and over the age of 18years are excluded as well as patients needing injection therapy to more than 5 joints
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective of this study is to evaluate the effectivity of intranasal dexmedetomidine sedation during intra-articular injection therapy. Intranasal dexmedetomidine is compared with dinitrous oxide (N2O) which has already been proven safe and effective sedation method during painful procedures in pediatric patients.
Read full original descriptionShow less
In earlier studies the median VAS during intra-articular corticosteroid injections with patients receiving nitrous oxide has been 3 (Uziel et al 2008). Study hypothesis is that with intranasal dexmedetomidine sedation the VAS pain levels will be 1 unit lower.
The 2 groups in the trial
- Intranasal dexmedetomidineTreatment being tested
Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
Treatment: Dexmedetomidine and Sedatives/Hypnotics,Other
- Nitrous oxide inhalationExisting treatment, for comparison
Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
Treatment: Dexmedetomidine and Sedatives/Hypnotics,Other
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 20 December 2023